SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple MyelomaPan Zhou(Zhengzhou University), Kai Sun(Zhengzhou University)Frontiers in PharmacologyApril 6, 202210.3389/fphar.2022.841308Cited by 6SaveCiteExport RISWatch citationsRelated PapersOverexpression of PRDM5 promotes acute myeloid leukemia cell proliferation and migration by activating the JNK pathway|Cancer Medicine|2019|7